Unique ID issued by UMIN | UMIN000018788 |
---|---|
Receipt number | R000021732 |
Scientific Title | Tissue-engineered cultured periosteum used with platelet-rich plasma and hydroxyapatite in treating human osseous defects: second phase of clinical trial. |
Date of disclosure of the study information | 2015/08/24 |
Last modified on | 2017/08/25 11:39:22 |
Tissue-engineered cultured periosteum used with platelet-rich plasma and hydroxyapatite in treating human osseous defects: second phase of clinical trial.
Clinical effect of cultured periosteal sheet for treating chronic periodontitis.
Tissue-engineered cultured periosteum used with platelet-rich plasma and hydroxyapatite in treating human osseous defects: second phase of clinical trial.
Clinical effect of cultured periosteal sheet for treating chronic periodontitis.
Japan |
Chronic periodontitis
Dental medicine |
Others
NO
To evaluate the safety and efficacy of a new therapy to treat periodontal defect using tissue-engineered periosteum, platelet-rich plasma and artificial bone material.
Safety,Efficacy
Phase II
Clinical Attachment Levelat 12-month postsurgery.
Radiographic Infrabony Defect Depth at 12-month postsurgery.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Other |
Single arm
1. 30 patients
2. At periodontal surgery after
debridement, the coagulated platelet-rich
plasma and hydroxyapatite granules was
placed into the defect and then cultured
periosteal sheet was overlaid onto them
as interventions.
20 | years-old | <= |
80 | years-old | >= |
Male and Female
1. 20 years or older and 80 years younger persons who obtained written informed consent.
2. Persons satisfied with a standard of biosafety level 1.
3. Free of systemic complications.
4. Completion of periodontal initial treatment.
5. Accept for periodontal surgery.
6. Persons who had one infrabony defect with probing depth: 6mm and more, clinical attachment level:6mm and more. Osseous defect depth estimated to be 4mm and more radiographically.
1. Persons who do not accept written informed consent.
2. Persons not satisfied with a standard of biosafety level 1.
3. Persons who had severe systemic complications.
4. Un-completion of periodontal initial treatment.
5. Persons who were unable to accept for periodontal surgery.
6. Persons who had not one infrabony defect with probing depth: 6mm and more, clinical attachment level: 6mm and more. and osseous defect depth estimated to be 4mm and more radiographically.
7. Persons who had the allergy due to medication.
8. Persons who are judged to be unqualified for this study subjects by investigators.
30
1st name | |
Middle name | |
Last name | Kazuhiro Okuda |
Niigata University
Graduate School of Medical and Dental Sciences
2-5274 Gakkocho-dori, Chuo-ku, Niigata, 951-8514 Japan
0252272870
okuda@dent.niigata-u.ac.jp
1st name | |
Middle name | |
Last name | Kazuhiro Okuda |
Niigata University
Graduate School of Medical and Dental Sciences
2-5274 Gakkocho-dori, Chuo-ku, Niigata, 951-8514 Japan
0252272870
okuda@dent.niigata-u.ac.jp
Niigata University
1)Niigata University Clinical Research Fund
2)Grant-in-Aid for Scientific Research
from the Ministry of Education, Sports,
Science, and Technology, Japan.
Other
NO
2015 | Year | 08 | Month | 24 | Day |
Published
Completed
2006 | Year | 05 | Month | 20 | Day |
2007 | Year | 01 | Month | 18 | Day |
2015 | Year | 08 | Month | 24 | Day |
2017 | Year | 08 | Month | 25 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021732